Effect of Ustekinumab on Extraintestinal Diseases in Refractory Crohn's Disease

J Crohns Colitis. 2021 Aug 2;15(8):1399-1400. doi: 10.1093/ecco-jcc/jjab028.

Authors

Antonio Tursi^{1

2}, Giammarco Mocci³, Giovanni Maconi⁴

Affiliations

¹ Territorial Gastroenterology Service, Azienda Sanitaria Locale Barletta-Andria-Trani [ASL BAT], Andria [BT], Italy.
² Department of Medical and Surgical Sciences, Postgraduate School of Digestive Diseases, Catholic University, Rome, Italy.
³ Division of Gastroenterology, 'Brotzu' Hospital, Cagliari, Italy.
⁴ Division of Gastroenterology, 'L. Sacco' University Hospital, Milan, Italy.

PMID: 33580249
DOI: 10.1093/ecco-jcc/jjab028

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Crohn Disease / complications*
Crohn Disease / drug therapy*
Female
Follow-Up Studies
Humans
Immunologic Factors / therapeutic use*
Induction Chemotherapy
Male
Middle Aged
Treatment Outcome
Ustekinumab / therapeutic use*
Young Adult

Substances

Immunologic Factors
Ustekinumab